Amgen (AMGN) reported $9.09 billion in income for the quarter ended December 2024, representing a year-over-year enhance of 10.9%. EPS of $5.31 for a similar interval compares to $4.71 a yr in the past.
The reported income compares to the Zacks Consensus Estimate of $8.86 billion, representing a shock of +2.54%. The corporate delivered an EPS shock of +5.57%, with the consensus EPS estimate being $5.03.
Whereas buyers scrutinize income and earnings modifications year-over-year and the way they evaluate with Wall Avenue expectations to find out their subsequent transfer, some key metrics at all times supply a extra correct image of an organization’s monetary well being.
As these metrics affect top- and bottom-line efficiency, evaluating them to the year-ago numbers and what analysts estimated helps buyers mission a inventory’s value efficiency extra precisely.
Right here is how Amgen carried out within the simply reported quarter by way of the metrics most generally monitored and projected by Wall Avenue analysts:
- Product Gross sales- EPOGEN- U.S. $19 million versus $34.61 million estimated by eight analysts on common. In comparison with the year-ago quarter, this quantity represents a -65.5% change.
- Product Gross sales- Neulasta- U.S. $72 million versus the seven-analyst common estimate of $106.76 million. The reported quantity represents a year-over-year change of -65.4%.
- Product Gross sales- Neulasta- ROW: $26 million in comparison with the $24.37 million common estimate primarily based on seven analysts. The reported quantity represents a change of -16.1% yr over yr.
- Product Gross sales- Otezla- U.S. $514 million versus $499.93 million estimated by six analysts on common. In comparison with the year-ago quarter, this quantity represents a -2.3% change.
- Product Gross sales- BLINCYTO- Complete: $381 million in comparison with the $341.94 million common estimate primarily based on 10 analysts. The reported quantity represents a change of +58.1% yr over yr.
- Product Gross sales- Repatha- Complete: $606 million in comparison with the $555.05 million common estimate primarily based on 10 analysts. The reported quantity represents a change of +45.3% yr over yr.
- Product Gross sales- KYPROLIS- Complete: $372 million versus the 10-analyst common estimate of $385.99 million.
- Product Gross sales- Vectibix- Complete: $246 million versus $274 million estimated by 10 analysts on common.
- Product Gross sales- Enbrel- Complete: $1.02 billion versus the 10-analyst common estimate of $863.80 million.
- Income- Different revenues: $370 million versus $377.86 million estimated by 10 analysts on common. In comparison with the year-ago quarter, this quantity represents a +1.9% change.
- Product Gross sales- Neulasta- Complete: $98 million versus the 10-analyst common estimate of $121.89 million. The reported quantity represents a year-over-year change of -59%.
- Income- Product gross sales: $8.72 billion versus the 10-analyst common estimate of $8.48 billion. The reported quantity represents a year-over-year change of +11.3%.
View all Key Company Metrics for Amgen here>>>
Shares of Amgen have returned +11.7% over the previous month versus the Zacks S&P 500 composite’s +1% change. The inventory presently has a Zacks Rank #3 (Maintain), indicating that it might carry out according to the broader market within the close to time period.
Zacks’ Analysis Chief Names “Inventory Most More likely to Double”
Our group of specialists has simply launched the 5 shares with the best likelihood of gaining +100% or extra within the coming months. Of these 5, Director of Analysis Sheraz Mian highlights the one inventory set to climb highest.
This high choose is among the many most modern monetary corporations. With a fast-growing buyer base (already 50+ million) and a various set of innovative options, this inventory is poised for giant features. In fact, all our elite picks aren’t winners however this one might far surpass earlier Zacks’ Shares Set to Double like Nano-X Imaging which shot up +129.6% in little greater than 9 months.
Free: See Our Top Stock And 4 Runners Up
Amgen Inc. (AMGN) : Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the creator and don’t essentially mirror these of Nasdaq, Inc.
